Me interesó este estudio:
Reversal of cognitive decline: A novel therapeutic program
Dale
E. Bredesen
Abstract
This
report describes a novel, comprehensive, and personalized therapeutic
program that is based on the underlying pathogenesis of Alzheimer's
disease, and which involves multiple modalities designed to achieve
metabolic enhancement for neurodegeneration (MEND). The first 10 patients
who have utilized this program include patients with memory loss associated
with Alzheimer's disease (AD), amnestic mild cognitive impairment (aMCI),
or subjective cognitive impairment (SCI). Nine of the 10 displayed
subjective or objective improvement in cognition beginning within 3-6
months, with the one failure being a patient with very late stage AD. Six
of the patients had had to discontinue working or were struggling with
their jobs at the time of presentation, and all were able to return to work
or continue working with improved performance. Improvements have been
sustained, and at this time the longest patient follow-up is two and
one-half years from initial treatment, with sustained and marked improvement.
These results suggest that a larger, more extensive trial of this
therapeutic program is warranted. The results also suggest that, at least
early in the course, cognitive decline may be driven in large part by
metabolic processes. Furthermore, given the failure of monotherapeutics in
AD to date, the results raise the possibility that such a therapeutic
system may be useful as a platform on which drugs that would fail as
monotherapeutics may succeed as key components of a therapeutic system.
Se puede leer completo en:
http://www.impactaging.com/papers/v6/n9/full/100690.html
Tiene una tabla interesante con un plan donde se pueden ver los nutrientes que utilizan para mejorar aspectos cognitivos:
